Suspicious features for malignancy include irregular shape, irregular margins, micro-calcifications, depth greater than width, and markedly hypoechoic solid lesions.9 The British Thyroid Association (BTA) classified TNs into 5 categories; U1 = normal thyroid gland, U2 = benign
TN, U3 = intermediate/equivocal TN, U4 = suspicious TN, and U5 = malignant TN.10 Both EU-TIRADS and BTA help physicians and radiologists in predicting the nature of thyroid lesions and selecting patients for fine-needle aspiration (FNA) cytology.
The goal of the present study was to prospectively examine VTIQ SWE and B-mode and Doppler US, individually and combined, for their ability to differentiate benign
and malignant CLNs.
The data related to benign
ovarian neoplasms as well as malignant ovarian tumours diagnosed on the basis of their histopathological features.
Therefore, in a patient with cancer, the differentiation between benign
and malign effusion is of great importance.
To identify likely benign
nodules, results were integrated with a clinical risk prediction model.
Of the 136 ovarian tumours 92 cases were benign
(67.6%), 3 were borderline (2.2%) and 41 were malignant (30.2%) based on histopathological examination.
The research, published in the Annals of Oncology journal, found that the CNN missed fewer melanomas and misdiagnosed benign
moles less often than a group of human dermatologists.
Researchers from The Ohio State University found that among 47 indeterminate cases that underwent Afirma GSC testing, the next-generation test identified nearly three fourths (72.3%) of the patients as benign
. This was significantly higher than the nearly half (48.4%) that were identified as benign
by GEC testing from 2011 thorough mid-2017.
Key Words: Breast lumps, Fibroadenoma, Benign
breast disorders, Fine needle aspiration cytology
Both nodules were well circumscribed, compatible with benign
However, MRI has limited specificity with an overlap in the appearance of benign
and malignant lesions.
Ultrasonography (USG) is considered the primary imaging modality for confirmation of the ovarian origin of the mass and characterization of the nature of the mass as benign